Videos

NP Theresa Stukus and NP Nelli Zafman discuss how recent advances in frontline antibody-drug conjugate (ADC) therapy are enabling a more individualized approach to the management of metastatic triple-negative breast cancer (mTNBC).

Beth Sandy, CRNP, of Penn Medicine explains how oncology nurses and pharmacists collaborate to manage financial toxicity and secure oral therapies.

First-line amivantamab+lazertinib may rewire EGFR-mutant NSCLC, curb resistance, and boost survival — plus proactive clinic management tips.

How chemo-free lung cancer combos like amivantamab+lazertinib boost survival, with tips to manage rashes and stay on therapy.

Prophylactic anticoagulation cuts VTE in lung cancer and helps patients stay on EGFR-targeted combos longer.

Proactive prophylaxis with amivantamab and lazertinib cuts rash, paronychia, and clots using daily skincare, antibiotics, and anticoagulation to keep patients on therapy.

Early COPERNICUS results show subcutaneous amivantamab and proactive VTE and skin prophylaxis sharply reduce reactions, helping NSCLC patients stay on therapy.

This opening segment introduces low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) and establishes the anatomic and diagnostic vocabulary the rest of the program relies on.

At the 29th APAO Symposium, Mark Honor, PA-C, discussed the collaborative care model and the vital role of PAs in managing day-to-day oncology care.

NP Theresa Stukus and NP Nelli Zafman discuss the expanding role of oncology nurse practitioners and advanced practice providers in delivering comprehensive care for patients with metastatic triple-negative breast cancer (mTNBC).

At the 29th APAO Symposium, Jennifer Fisher, PA-C, discussed combining surgery, radiation, and novel systemic drugs to treat brain metastases.

At the 29th APAO Symposium, Dr. Angela Jia highlighted the critical role of PAs and NPs in managing toxicities and applying new ASCO data.

At the 29th APAO Symposium, Lifetime Achievement Award honoree Colleen Tetzlaff, PA-C, shared insights on adapting to rapid clinical advancements.

Kelsey Martin, APRN, discusses the tolerability and clinical benefits of frontline antibody-drug conjugates for metastatic TNBC.

Experts at the 2026 APAO Symposium highlighted patient education, clinical trial updates, and professional development in cancer care.

Kennon McCollum explains how psychosocial, physical, and financial barriers impact treatment selection for patients with CLL.

Andrew Evens, DO, and Joanna Rhodes, MD, discuss evolving CLL treatment paradigms, CAR T-cell therapy versus bispecific antibodies, and expanding community access to specialized lymphoma care.

NP Theresa Stukus and NP Nelli Zafman discuss the essential role of comprehensive biomarker testing in guiding individualized treatment decisions for patients with metastatic triple-negative breast cancer (mTNBC).

NP Theresa Stukus and NP Nelli Zafman discuss how recent clinical trial data, updated clinical practice guidelines, and new FDA approvals are influencing frontline treatment decisions for metastatic triple-negative breast cancer (mTNBC).

How oncology nurses can dismantle patient myths, secure early dietitian referrals, and collaborate to optimize supportive care like vitamin D.

Oncology clinical trial nurse navigator Elise Curry, RN, explains the impact of the FDA's approval of oral iberdomide for multiple myeloma.

Why first-line choices matter in metastatic TNBC: many miss second-line care, and new antibody-drug conjugates boost survival over chemo.

Oncology NPs discuss new frontline options for metastatic triple-negative breast cancer, using cases to guide therapy choice and manage toxicities.

A social worker explains how patient "difficulties" are often trauma-based fight, flight, freeze, or fawn responses to a health crisis.

Dr. Michael Wong discusses clinical workflows, dosing calculations, and biosafety protocols for the newly approved Tudriqev-nivolumab regimen.

A new study reveals global gaps in integrative oncology knowledge, highlighting communication and the role of APPs in community settings.

New Phase 3 ENDURANCE trial data shows no survival benefit for indefinite lenalidomide maintenance over 2 years in non-transplant myeloma patients.

Theresa Lynne Harrington Stukus, ANPBC NP, discusses managing the influx of new breast cancer therapies and the importance of professional networking.